Clinical Trial Update: MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial of MM-398 (Nal-IRI) investigates tumor drug levels and feasibility of using ferumoxytol-enhanced MRI to measure tumor-associated macrophages and p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors
• Triple-negative Breast Cancer

Drugs mentioned

• MM-398 (Nanoliposomal Irinotecan, Nal-IRI) (Nal-IRI)

Snippet

Sponsor: Ipsen | Conditions: Solid Tumors, ER/PR Positive Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-10-28